SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Formerly About Advanced Micro Devices
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tenchusatsu who wrote (1331785)12/3/2021 12:21:05 PM
From: Broken_Clock  Read Replies (1) of 1573213
 
ncbi.nlm.nih.gov
Vaccine. 2021 Apr 15; 39(16): 2190–2200.

5. Concluding remarksmRNA is a rising star in the field of biopharmaceuticals. The interest in this new type of vaccine derives from the flexibility, safety, and precision that these vaccines present when compared to conventional approaches. The growing number of clinical trials for cancer therapies and infectious diseases demonstrates an increased interest from the industry to release these types of vaccines to the market. mRNA vaccines are precise, safe and flexible, which can be easily manufactured on a large scale for clinical grade applications. These vaccines can be an answer to quickly respond to epidemic outbreaks in terms of manufacturing.

However, to achieve this status, the development of sustainable and cost-effective manufacturing processes must be addressed. Although the IVT reaction of mRNA is safer and quicker than most of the established vaccines production, it relies on the use of expensive and limited materials. Downstream processing of the vaccine is still poorly established, and it is dependent on methods that lack scalability and cost-effectiveness. Moving the process to continuous manufacturing can overcome these bottlenecks. We propose a microfluidics approach with the compartmentalisation of enzymatic reactions coupled with in situ product removal (ISPR) and substrate feed and product recovery (SDPR) modules and the use of multimodal chromatography to replace the use of multiple chromatographic steps ( Fig. 5). The use of new production methods that allow the reuse and recirculation of compounds integrated with high-throughput purification and well-defined analytical methods in a continuous manufacturing process can be the answer for a sustainable, flexible and cost-effective vaccine manufacture that can allow an on-demand response.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News